An Expert Panel Questionnaire for Assessing Patient-Reported and Clinician-Reported Outcomes in Actinic Keratosis
Year: 2022
Type: article
Abstract: Timely, effective treatment of actinic keratoses (AKs) is important because there is no reliable way to predict which of these hyperkeratotic lesions on chronically sun-exposed skin will become cancerous. 1,2 • Some topical treatments for AKs such as 5-fluorouracil and imiquimod are associated with uncomfortable and visible local skin reactions (LSRs), which have been linked to poor treatment tolerability and low treatment satisfaction. 3,4• Clinical trials of AK have not typically included patient-reported outcomes (PROs).• AK treatment-related factors such as skin reactions are known to impact QOL and treatment adherence. 5• Current assessments on topical treatment attributes in AK do not evaluate safety, effectiveness, and satisfaction from both clinician and patient perspectives, creating an unmet need for more comprehensive AK-specific measures that fully capture the patient experience. 3,6,7• An AK-specific PRO instrument may help highlight patient centric issues and outcomes in clinical studies and real-world clinical practices.• Comparing current and previous AK treatments would be useful in gauging the relative impact of different treatments.Further, simultaneously assessing PROs and clinician reported outcomes (ClinROs) on treatment attributes may enhance clinician-patient communication, providing great utility among clinical practitioners.
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4309317341